Thermo Fisher Scientific Ranibizumab Monoclonal Antibody (10D12)
Ranibizumab을 인식하는 마우스 단클론 항체로 ELISA에 적합합니다. 인간 VEGF-A 결합 억제 연구에 활용됩니다. 동결건조 형태로 제공되며 PBS 완충액에 0.02% sodium azide를 포함합니다. -20°C 이하에서 보관 권장.
- 카탈로그번호
- A0203640
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific Ranibizumab Monoclonal Antibody (10D12)
Applications
ELISA (ELISA)
- Tested Dilution: 0.01–0.1 µg/mL
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host / Isotype | Mouse / IgG1, kappa |
| Class | Monoclonal |
| Type | Antibody |
| Clone | 10D12 |
| Immunogen | Ranibizumab |
| Conjugate | Unconjugated |
| Form | Lyophilized |
| Purification | Protein A |
| Storage Buffer | PBS, pH 7.4 |
| Contains | 0.02% sodium azide |
| Storage Conditions | -20°C or -80°C if preferred |
| Shipping Conditions | Ambient (domestic); Wet ice (international) |
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Ranibizumab (trade name Lucentis) is an FDA-approved drug used to treat patients with neovascular (wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment that binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity.
Anti-Ranibizumab Antibody (10D12), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ranibizumab.
Target Information
Ranibizumab (Lucentis) is an FDA-approved recombinant humanized IgG1 kappa monoclonal antibody fragment targeting VEGF-A. It binds and inhibits VEGF-A activity, preventing abnormal blood vessel growth associated with AMD and RVO.
For Research Use Only.
Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기
문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.